Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

• Status: Recruiting
• Trial end date: 2022-09-15
• Target enrollment: 0
• Participant gender: All

Summary

To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alan Bryce
• Treatments: Camostat

Criteria

Inclusion Criteria:

• Laboratory confirmed SARS-CoV-2 infection

• Admitted to hospital for management of SARS-CoV-2

• Age ≥18

• Subject or legal representative able to give informed consent

• Ability to take all study drugs

• Respiratory status of 3 or greater on the WHO ordinal scale

• ALT or AST ≤5 x ULN

• Creatinine clearance ≥50 mL/min using the Cockroft-Gault formula

• Willingness to provide mandatory specimens for correlative research and banking

Exclusion Criteria:

• Women who are pregnant or breastfeeding

• Known hypersensitivity to the study drug, the metabolites or formulation excipient